Archie's Corner

[Archangel]

VRDE, a .20 cents plus play??? might be>>>>>

ADVR News (.24):
The Therapeutic Potential Of Product R And National Security:
These are trying times for the United States. Terrorists have declared biologic warfare on the citizens of this country. The mailing of letters contaminated with the Anthrax bacillus now dominates the news. However, the possible introduction of smallpox into the population of the United States via contaminated material or infected terrorists would cause such great morbidity and mortality, that the problem of anthrax infection would appear insignificant in comparison.
Reticulose has been used effectively to treat generalized vaccinia virus infection. (Reynolds, M.R. Arch. Ped. 77:421, 1960) The vaccinia virus is derived from the virus that causes cowpox and is the virus used to prepare the smallpox vaccine. The cowpox virus and the human smallpox virus are very similar. The fact that Reticulose was used successfully to treat generalized vaccinia virus infection, a complication of smallpox vaccination, raises the possibility, Product R, may be effective in the treatment of smallpox virus infection.

The broad based activity of Product R against viral infections also raises the possibility that Product R might be effective in treating more exotic but very lethal infections.

The Company has communicated the potential benefits of Product R to United States agencies evaluating the readiness of our National Security.

Shalom Z. Hirschman, M.D.
Product R is a non-toxic peptide nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, Product R has been termed a «switch type» immunomodulator. Product R has direct antiviral effects against select viruses such as adenovirus and human papilloma virus. Product R has shown promise in its ability to mitigate the toxic side effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers.
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that ADVR will be able to secure the financing necessary to complete the clinical trials of Product R. ADVR undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
------------

VRDE news (.095):

Tuesday October 23, 10:27 am Eastern Time
Press Release
SOURCE: Veridien Corporation
EPA Approves New Kill Claims for Veridien's Disinfectant Formula
Next Generation Viraguard® Reduces Threat of Disease Transmission Highlighted by Recent Bioterrorism Concerns; Infection Control Team Working to Find Solutions

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Oct. 23, 2001-- Veridien Corporation (OTCBB:VRDE - news) announced today that they have received Environmental Protection Administration (EPA) approval for the next generation liquid disinfectant in their Viraguard® product line. Viraguard® Hospital Disinfectant/Cleaner and Instrument Presoak completely eradicates eight categories of bacteria, including Staphylococcus aureus, Streptococcus pyogenes, Salmonella choleraesuis, Pseudomonas aeruginosa, and deadly E-coli that has caused numerous deaths associated with food contamination. EPA also now recognizes the product as effective against mutated bacterial strains, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecium (VRE). The EPA approval also recognizes the ability to kill Mycobacterium tuberculosis (TB), an encapsulated and harder to kill bacterial form. Effectiveness against these resistant strains is of particular importance to hospital and allied health professionals who insist on those claims being included on any product they purchase for surface disinfection. The EPA approval also recognizes the effectiveness of Viraguard® on seven virus categories including, but not limited to, HIV, Herpes, and Influenza, as well as effectiveness against the most common source of fungus infection.

Sheldon Fenton, President and CEO of Veridien Corp. stated, ``Our commitment to bringing safe and effective disinfectant and antimicrobial products to the marketplace compels us to continue our research and development program towards finding new solutions to the natural and man made environmental challenges we face.'' Mr. Fenton continued, ``With the current threat of bioterrorism, and Veridien's decade long track record of confronting infection control challenges, we will utilize all our expertise and resources to help safeguard workplaces and homes.''

Viraguard® is approved for use on hard non-porous surfaces as a disinfectant and deodorizer for hospitals, clinics, medical offices, nursing homes, ambulances, hotels, restaurants, schools, health spas, and rest room facilities. Viraguard® leaves no harmful residue on the surfaces that it cleans and disinfects. Residue from other products is associated with the development of so-called ``Superbugs'' that are similar to the mutated resistant strains of bacteria that Viraguard® is proven to kill. The Viraguard® formulation is also available in a convenient towelette canister.

Viraguard® is the only hard surface disinfectant formula that is also registered with the U.S. Food and Drug Administration for use as an antimicrobial skin cleanser, available as a liquid spray, towelette, and clear hand gel.

Approval has also been granted by the Canadian Ministry of Health (Health Canada) for the use of the new Viraguard® in institutional medical settings and in the home as an antiseptic skin cleanser (Drug Identification Number issued) and as hard surface disinfectant (PCP Number issued).

Veridien has convened a panel of experts to expedite the review of the findings and implications of ongoing tests of various Viraguard® existing and developmental formulations including effectiveness against Bacillus anthracis, the bacteria that causes Anthrax, and against the family of bacillus associated with the transmission of Small Pox. Veridien's infection control team is focusing on possible solutions to deal with recent events of national concern.

About Veridien Corporation

Veridien Corporation is a Health Care Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed patented and unique products including surface disinfectants, antiseptic hand gels, a multi-use skin and surface cleanser, contact lens care, and sun protectant products. The flagship product Viraguard® Hospital Disinfectant/Cleaner and Instrument Presoak is a patented, EPA registered, surface disinfectant, environmentally friendly and nontoxic by OSHA Standard 29 CFR 1910.1200. Viraguard® Antiseptic Hand Gel is an FDA drug listed product utilizing a patented Veridien formulation. Veridien's product lines are currently sold internationally through a variety of well-known distributors representing Medical, Dental, Food, Retail and Specialty markets. Veridien's products are also available under private label. Veridien is currently expanding sales to nationally and regionally known retail market chains and have expanded sales through E-Commerce.

Look for Veridien at: http://www.vrde.com; and The SunSwipe Corporation L.L.C. at: http://www.sun-swipe.com





Arch